Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The Standalone Quarterly and Half Yearly Results ....
Awaiting price reaction for this filing.
The Board of Directors of Blueblood Ventures Limited, at its meeting held on November 14, 2025, approved the standalone unaudited financial results for the half year ended September 30, 2025. Revenue from operations jumped sharply to Rs. 100.79 lakhs from Rs. 17.94 lakhs in the same period last year, while total revenue stood at Rs. 110.40 lakhs. The company swung to a profit after tax of Rs. 16.98 lakhs (EPS of Rs. 0.57), compared with a loss of Rs. 0.23 lakhs in H1 FY25. Statutory auditor KRA & Associates issued an unmodified review opinion, but highlighted concerns including 247 Zero Optional Convertible Debentures (worth Rs. 247 lakhs) wrongly transferred to a third party, unconfirmed long-term loans and advances of Rs. 6,188.55 lakhs treated as recoverable, and negative cash flow from operations of Rs. 491.69 lakhs. Total assets stood at Rs. 10,053.42 lakhs.
The strong revenue growth and return to profitability are positive for shareholders, but the large unconfirmed receivables, the wrongly transferred ZOCDs, and weak operating cash flow raise red flags about earnings quality and asset recovery. Investors should watch for further clarity on the disputed ZOCDs and recovery of the Rs. 6,188.55 lakhs in long-term loans and advances.